Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?

Area of Science:

• Hepatology
• Virology
• Public Health

Background:

• India shoulders a significant global burden of hepatitis C virus (HCV) infection.
• Unsafe medical practices and blood transfusions are primary transmission routes in India.
• HCV genotype 3 is most prevalent, followed by genotype 1.

Purpose of the Study:

• To evaluate the efficacy of generic direct-acting antivirals (DAAs) compared to branded drugs in the Indian context.
• To assess the role of cost-effective generic DAAs in controlling HCV in India.
• To review real-world data on generic DAA use in special patient populations.

Main Methods:

• Analysis of existing studies on generic DAAs in India and internationally.
• Examination of real-life data and prospective studies in high-risk groups.
• Evaluation of efficacy and cost-effectiveness of generic DAA therapies.

Main Results:

• Generic DAAs demonstrate comparable efficacy to branded medications.
• Cost of therapy remains a significant barrier to HCV control, highlighting the importance of generic options.
• Data supports the use of generic DAAs in diverse patient groups, including those with hematological disorders, kidney disease, and transplant recipients.

Conclusions:

• Generic DAAs are essential for effective and affordable HCV control in India.
• A multi-pronged approach, including education and treatment of existing cases, is necessary.
• Reducing the incidence of new infections alongside treating current cases is vital to decrease HCV-related mortality.